{"id":10793,"date":"2016-12-07T07:01:13","date_gmt":"2016-12-07T07:01:13","guid":{"rendered":"http:\/\/revoscience.com\/en\/?p=10793"},"modified":"2016-12-07T07:01:13","modified_gmt":"2016-12-07T07:01:13","slug":"new-effective-strategy-producing-flu-vaccines","status":"publish","type":"post","link":"https:\/\/www.revoscience.com\/en\/new-effective-strategy-producing-flu-vaccines\/","title":{"rendered":"New, more effective strategy for producing flu vaccines"},"content":{"rendered":"<figure id=\"attachment_10795\" aria-describedby=\"caption-attachment-10795\" style=\"width: 615px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-10795\" src=\"http:\/\/revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg\" alt=\"Yoshihiro Kawaoka, a professor of pathobiological sciences in the School of Veterinary Medicine at UW\u2013Madison, talks with a group of media representatives during a tour of the Influenza Research Institute in February 2013. PHOTO: BRYCE RICHTER \" width=\"615\" height=\"414\" title=\"\"><figcaption id=\"caption-attachment-10795\" class=\"wp-caption-text\">Yoshihiro Kawaoka, a professor of pathobiological sciences in the School of Veterinary Medicine at UW\u2013Madison, talks with a group of media representatives during a tour of the Influenza Research Institute in February 2013. PHOTO: BRYCE RICHTER<\/figcaption><\/figure>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">A team of researchers led by <a style=\"color: #000000;\" href=\"https:\/\/www.vetmed.wisc.edu\/people\/kawaokay\/\" target=\"_blank\" rel=\"noopener\">Yoshihiro Kawaoka<\/a>, professor of pathobiological sciences at the University of Wisconsin\u2013Madison School of Veterinary Medicine, has developed technology that could improve the production of vaccines that protect people from influenza B.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">That technology is an influenza B vaccine virus \u201cbackbone\u201d that would allow producers to grow vaccine viruses at high yield in mammalian cell culture rather than in eggs. Using the backbone as a template to add vaccine-virus-specific components, it would offer protection against both lineages of influenza B that circulate in the human population.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">\u201cWe want to provide a system that produces influenza vaccines that are more efficacious,\u201d says Kawaoka. \u201cIt is better to produce influenza viruses for vaccine production in cells instead of eggs, but the problem is that influenza virus does not grow well in cell culture compared with embryonated eggs.\u201d<\/span><\/p>\n<figure id=\"attachment_10796\" aria-describedby=\"caption-attachment-10796\" style=\"width: 300px\" class=\"wp-caption alignright\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-10796 size-medium\" src=\"http:\/\/revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Influenza-Virus-from-CDC-e1480953423737-500x500-300x300.jpg\" alt=\"Illustration showing the different features of an influenza virus, including the surface proteins hemagglutinin (blue) and neura-minidase (red). CENTERS FOR DISEASE CONTROL AND PREVENTION \" width=\"300\" height=\"300\" title=\"\" srcset=\"https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Influenza-Virus-from-CDC-e1480953423737-500x500-300x300.jpg 300w, https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Influenza-Virus-from-CDC-e1480953423737-500x500-150x150.jpg 150w, https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Influenza-Virus-from-CDC-e1480953423737-500x500.jpg 500w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><figcaption id=\"caption-attachment-10796\" class=\"wp-caption-text\">Illustration showing the different features of an influenza virus, including the surface proteins hemagglutinin (blue) and neura-minidase (red). CENTERS FOR DISEASE CONTROL AND PREVENTION<\/figcaption><\/figure>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">The new technology may overcome that challenge. The team published its results Monday, Dec. 5, in the <a style=\"color: #000000;\" href=\"http:\/\/www.pnas.org\/\" target=\"_blank\" rel=\"noopener\">Proceedings of the National Academy of Sciences<\/a>.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Each year, the U.S. Food and Drug Administration, in collaboration with the Centers for Disease Control and Prevention and the World Health Organization, decides which strains of influenza virus to include in the seasonal flu vaccine. It typically includes two influenza A strains and two influenza B strains.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Growing vaccine viruses in high-yield cell culture should improve the ability of seasonal vaccines to protect against influenza A and B because vaccine viruses grown in mammalian cell culture are less likely to mutate compared to those grown in eggs. Mutations can lead to vaccine viruses that no longer match the intended strains of influenza.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">\u201cIt may still not be perfect, but it will at least be substantially better than current vaccines,\u201d says Kawaoka, who notes no one else has successfully tried to produce high-yield influenza B vaccine virus before now. Last year, his research team created a <a style=\"color: #000000;\" href=\"http:\/\/news.wisc.edu\/new-strategy-could-yield-more-precise-seasonal-flu-vaccine\/\" target=\"_blank\" rel=\"noopener\">high-yield influenza A<\/a> vaccine virus candidate for cell culture production.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\"><a style=\"color: #000000;\" href=\"http:\/\/www.cdc.gov\/flu\/protect\/vaccine\/cell-based.htm\" target=\"_blank\" rel=\"noopener\">Per the CDC<\/a>, growing vaccine viruses in high-yield cell culture may also enable faster and potentially greater production of vaccine. This could improve the ability of health officials to respond during an influenza pandemic.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">To develop the influenza B vaccine virus backbone, Kawaoka\u2019s team screened influenza B viruses for random genetic mutations that led to improved replication.<\/span><\/p>\n<p style=\"text-align: justify;\">[pullquote]The team identified the characteristics of each backbone that contributed to their improved yield and also found the backbones to be genetically stable. However, Kawaoka points out that more testing is required to discern whether they would increase vaccine virus yield under industrial conditions.[\/pullquote]<\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Using these mutants as templates, the researchers attached the genes that code for the surface proteins that trigger the human immune response (and thus offer protection in vaccinated individuals) \u2014 HA (hemagglutinin) and NA (neuraminidase). They selected the combinations of backbone mutations that supported better growth in cell culture, identifying two candidate backbones that led to higher amounts of vaccine virus.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">The team identified the characteristics of each backbone that contributed to their improved yield and also found the backbones to be genetically stable. However, Kawaoka points out that more testing is required to discern whether they would increase vaccine virus yield under industrial conditions.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Several companies and federal agencies have already contacted him about the influenza A and influenza B backbones, Kawaoka says, and he is hopeful the systems can be adopted by vaccine manufacturers and grown in cell culture facilities already available in the United States and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Kawaoka\u2019s goal is to help develop more effective vaccines to protect people from influenza infection. According to the CDC, influenza sickens millions, hospitalizes hundreds of thousands, and kills tens of thousands of people each year in the U.S.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">\u201cThis is something we have to do,\u201d Kawaoka says.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Kawaoka credits the <a style=\"color: #000000;\" href=\"http:\/\/www.warf.org\/\" target=\"_blank\" rel=\"noopener\">Wisconsin Alumni Research Foundation<\/a> for the support to complete this work. \u201cWithout that, we couldn\u2019t get it going,\u201d he says.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">In addition to WARF, the current study was funded by the National Institute of Allergy and Infectious Diseases, Center for Research on Influenza Pathogenesis; Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Strategic Basic Research Program of the Japan Science and Technology Agency; and the Leading Advanced Projects for Medical Innovation from the Japan Agency for Medical Research and Development.<\/span><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>That technology is an influenza B vaccine virus \u201cbackbone\u201d that would allow producers to grow vaccine viruses at high yield in mammalian cell culture rather than in eggs. Using the backbone as a template to add vaccine-virus-specific components, it would offer protection against both lineages of influenza B that circulate in the human population.<\/p>\n","protected":false},"author":6,"featured_media":10795,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,26,17],"tags":[],"class_list":["post-10793","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biology","category-medicine","category-research"],"featured_image_urls":{"full":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",480,319,false],"thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231-150x150.jpg",150,150,true],"medium":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231-300x199.jpg",300,199,true],"medium_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",480,319,false],"large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",480,319,false],"1536x1536":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",480,319,false],"2048x2048":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",480,319,false],"ultp_layout_landscape_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",480,319,false],"ultp_layout_landscape":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",480,319,false],"ultp_layout_portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",480,319,false],"ultp_layout_square":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",480,319,false],"newspaper-x-single-post":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",480,319,false],"newspaper-x-recent-post-big":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",480,319,false],"newspaper-x-recent-post-list-image":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",95,63,false],"web-stories-poster-portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",480,319,false],"web-stories-publisher-logo":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",96,64,false],"web-stories-thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/12\/Flu_Lab_Tour13_3231.jpg",150,100,false]},"author_info":{"info":["Amrita Tuladhar"]},"category_info":"<a href=\"https:\/\/www.revoscience.com\/en\/category\/news\/biology\/\" rel=\"category tag\">Biology<\/a> <a href=\"https:\/\/www.revoscience.com\/en\/category\/health\/medicine\/\" rel=\"category tag\">Medicine<\/a> <a href=\"https:\/\/www.revoscience.com\/en\/category\/news\/research\/\" rel=\"category tag\">Research<\/a>","tag_info":"Research","comment_count":"0","_links":{"self":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/10793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/comments?post=10793"}],"version-history":[{"count":0,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/10793\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media\/10795"}],"wp:attachment":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media?parent=10793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/categories?post=10793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/tags?post=10793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}